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negative regulator in anti-tumor immunity.We found thatmetformin (Met) reduced tumor-inﬁltrating Treg (Ti-
Treg), particularly the terminally-differentiated CD103+KLRG1+ population, and also decreased effector mole-
cules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4+ T cells into inducible Treg (iTreg)
by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the eleva-
tion of phosphorylated S6 (pS6), a downstreammolecule of mTORC1. Rapamycin and compound C, an inhibitor
of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of
mTORC1 and AMPK. The metabolic proﬁle of iTreg, increased Glut1-expression, and reduced mitochondrial
membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-
treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.
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mTOR1. Introduction
Metformin (Met), themost widely prescribedﬁrst-line drug for type
2 diabetes (T2D), is a low cost and relatively safe therapeutic that has re-
cently garneredmore attention because of its anticancer effects. Several
epidemiologic studies have suggested that Met use may reduce cancer
incidence in T2D patients and, moreover, improve their prognosisin; Treg, T regulatory cell; FAO,
rating-T regulatory cell; CTLA4,
, killer cell lectin-like receptor
AMP-activated protein kinase;
orter 1; T2D, type 2 diabetes;
or-β1; RA, rapamycin; CC, com-
; TIL, tumor inﬁltrating lympho-
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, Okayama University Graduate
es, 2-5-1 Shikata-cho, Kita-ku,
).
.V. This is an open access article undcompared with those taking other drugs (Evans et al., 2005; Morales
and Morris, 2015; Noto et al., 2012). Regarding the mechanism, Met
has been suggested to directly inhibit the proliferation and invasion of
tumor cells and/or cancer stem cells (Song et al., 2012; Hirsch et al.,
2009; Shank et al., 2012), which could be explained by the downregula-
tion of the mammalian target of rapamycin (mTOR) kinase signaling,
following the activation of AMP-activated protein kinase (AMPK) in
tumor cells (Han et al., 2015; Zheng et al., 2013; Nair et al., 2014). How-
ever, the plasma concentration of Met in T2D patients is signiﬁcantly
lower (b20 μM) than the doses used in most experimental settings,
which could not explain the reduction of cancer incidence and/or
mortality.
Aside from the direct effect ofMet on cancer cells, the indirectmech-
anism including lowering glucose, insulin, and insulin-like growth fac-
tor in peripheral blood may be an alternative explanation, since those
factors promote tumor cell proliferation and expansion (Renehan
et al., 2006; Halje et al., 2012). Such indirect effects also involve our pre-
vious observations that oral administration of Met in drinking water
caused the rejection of solid tumors or reduced their growth in mice.
TheMet-induced antitumor effectwasmediated by the immune system
because the effect was completely abrogated in T cell-deﬁcient mice or
by in vivo depletion of CD8+ T cells by injection of a speciﬁc antibody
(Eikawa et al., 2015). We found this occurred through the activationer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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most of the original functions, such as the ability to producemultiple cy-
tokines and cytotoxicity. CD8+TILs ofmice exposed toMet begin to rap-
idly produce multiple cytokines, including interleukin-2 (IL-2), tumor
necrosis factor alpha (TNFα), and interferon gamma (IFNγ), and differ-
entiate into effector memory T cells (TEM); otherwise, central memory
T cells (TCM) are dominant in the tumor microenvironment. Since the
plasma concentration of Met inmice is comparable with that in T2D pa-
tients (Memmott et al., 2010), the perspective on the immune system
involvement might partly reconcile the signiﬁcant anticancer effects
with such a low plasma concentration of Met.
CD4+CD25+ regulatory T cells (Treg) has been implicated as a neg-
ative regulator for T cell mediated antitumor immunity (Nishikawa and
Sakaguchi, 2010; Adeegbe and Nishikawa, 2013; Facciabene et al.,
2012). In fact, depletion of Treg cells was shown to reject solid tumors
or to reduce tumor growth (Onizuka et al., 1999; Shimizu et al., 1999).
Therefore, the targeting of Treg cells is an attractive intervention for
cancer immunotherapy (Kurose et al., 2015). In this study, we show
thatMet administration decreased the number of Treg cells, particularly
terminally differentiated KLRG1+CD103+Treg cells (Joshi et al., 2015)
(i.e., active effector Treg cells), at tumor sites but not in peripheral lym-
phoid tissues by inducing apoptosis. The effect paralleled with
reprogramming of the metabolic state toward glycolysis and activation
of mTORC1. Approximation of in vitro study showed that Met pretreat-
ment of naïve CD4+CD25−T cells blocked its differentiation into TGFβ
dependent inducible Treg (iTreg) cells through downregulation of
Foxp3, a master transcription factor for Treg cells (Hori et al., 2003;
Fontenot et al., 2003). The Foxp3 downregulation in vitro also correlates
with elevation of glycolysis over oxidative phosphorylation, as indicated
by the results of Seahorse analyzer, and is dependent on activities of
mTORC1 and AMPK since speciﬁc inhibitors, rapamycin (RA) and com-
pound C (CC), restored the Foxp3 level, respectively. Thus, Met inhibits
TGF-β-dependent differentiation of Treg cells, which in turnmay gener-
ate a favorable state of sustained antitumor immunity in a tumor
microenvironment.2. Materials and Methods
2.1. Animals
BALB/c and C57BL/6 (B6) mice were purchased from SLC and CLEA
Japan. Foxp3GFP-cre mice were used previously (Miyao et al., 2012). All
mice were maintained in speciﬁc pathogen-free conditions in the ani-
mal facility of Okayama University. The studies have been approved
by an Institutional Animal Care and Use Committee of OkayamaUniver-
sity Graduate School of Medicine.2.2. Tumor Cell Lines
BALB/c ﬁbrosarcomaMethA, BALB/c radiation leukemia RLmale1, B6
ﬁbrosarcoma MCA, and B6 OVA gene-transduced B16 melanoma MO5
were used for the tumor assay. These tumor cell lines were used previ-
ously (Eikawa et al., 2015), except MCA (Boissonnas et al., 2010).2.3. Tumor Growth Assay
Mice were intradermally inoculated with tumor cells (MethA: 1.5
× 105, RLmale1: 2.0 × 105, MCA: 1.0 × 105, MO5: 2.0 × 105) on the
right back with a 27-gauge needle. Mice were orally administered
with Met hydrochloride (Tokyo Chemical Industry Co., Ltd., Japan) dis-
solved in drinking water (5 mg/mL). The long (a) and short (b) diame-
ters of the tumors weremeasured with a Vernier caliper, and the tumor
volume (V) was calculated according to the following equation: V= a×
b2/2.2.4. Isolation of TILs
Tumor tissues were dissected from the mice and minced into small
pieces in RPMI 1640 medium (Life Technologies, Tokyo, Japan). TILs
were harvested from the minced tumor tissues using a Medimachine
system (AS ONE, Osaka, Japan). Lymphocytes (TILs) could be distin-
guished from tumor cells since their size is less than half of that of
tumor cells under a microscope. Then, we stained all cells, including
TILs and tumor cells, with the indicated ﬂuorescence-labeled antibodies
and subjected them to ﬂow cytometric analysis.
2.5. CD4+CD25− T Cell Separation, In Vitro Induction, and Expansion of
iTreg Subsets
CD4+ CD25− T cells were isolated from B6 spleen cells by magnetic
separation (Miltenyi Biotec, Tokyo, Japan). CD4+CD25− T cells were in-
cubated with 10 μMMet or rotenone (0.1 μM) for 6 h, with or without
the mTORC1 inhibitor RA (Sigma–Aldrich) or the AMPK inhibitor CC
(Sigma–Aldrich). The cells were then stimulated with the immobilized
anti-CD3 mAb (3.0 μg/mL) (eBioscience, San Diego, CA, USA) or the
immobilized anti-CD3 mAb and soluble anti-CD28 mAb (2.0 μg/mL)
(eBioscience) in the presence or absence of TGF-β1 (5.0 ng/mL)
(PeproTech, Rocky Hill, NJ, USA). On day 3 after the stimulation with
the antibodies, the cells were harvested and cultured with recombinant
human (rh) IL-2 (5 IU/mL) (Takeda Pharmaceutical Company, Ltd.,
Osaka, Japan) for an additional 2 days.
2.6. Flow Cytometric Analysis
Cells were washed and incubated with mAbs for 30 min at 4 °C in
5 mM ethylenediaminetetraacetic acid and PBS containing 2% fetal calf
serum [ﬂuorescence-activated cell sorting (FACS) staining buffer]. The
following mAbs were used for cell surface marker staining: BV510-
conjugated anti-mouse CD3 (Biolegend, San Diego, CA, USA), PE-Cy7-
conjugated anti-mouse CD4 (Biolegend), APC-Cy7-conjugated anti-
mouse CD4 (Biolegend), APC-Cy7–conjugated anti-mouse CD8α
(Biolegend), BV421-conjugated anti-mouse CD25 (Biolegend), APC-
conjugated anti-mouse CD103 (Biolegend), PE-Cy7-conjugated anti-
mouse KLRG1 (Biolegend), PE-conjugated anti-mouse CTLA-4
(Biolegend), and APC-conjugated anti-mouse GLUT1 (rabbit monoclo-
nal antibody EPR3915, Abcam, Cambridge, MA, USA). A FITC-
conjugated anti-mouse IL-10 mAb (Biolegend) was used for intracellu-
lar cytokine staining. Intracellular cytokine staining was performed
with a ﬁxation/permeabilization kit (BD Biosciences). FITC- or APC-
conjugated anti-mouse Foxp3 (eBioscience), FITC-conjugated anti-
mouse pS6 (Cell Signaling Technology, CO, USA), and PE-conjugated
anti-mouse p-mTOR (BD Bioscience) antibodies were used for intracel-
lular staining using a Foxp3 staining buffer set (eBioscience) according
to the manufacturer's instructions. Early apoptosis was detected using
annexin-V-FITC and PE (Sigma–Aldrich). Mitochondrial ROS production
was detected using MitoSOX-PE (Thermo Fisher Scientiﬁc, Kanagawa,
Japan). To determine the mitochondrial membrane potential, we used
TMRE (tetramethylrhodamine, ethyl ester)-PE (Abcam). TMRE is a cat-
ionic, lipophilic dye that accumulates within the mitochondria of
healthy cells but not in those that have lost the membrane potential.
After staining, the cells were washed, suspended in the FACS staining
buffer, and analyzed on a FACS Canto IIﬂowcytometer (BDBiosciences).
We determined a suitable gate for lymphocytes (TILs) compared with
that of spleen cells. Tumor cells are always larger than TILs, as deter-
mined by the forward and side scatter pulse area (FSC-A and SSC-A).
The gated populations of lymphocytes (TILs) were identiﬁed as
CD4+CD8−, CD4−CD8+, and double-negative cells. On the other
hand, the gate for RLmale1 tumor cells only identiﬁed a CD4+CD8+
population, a unique phenotype of RLmale1 cells as thymus-derived
radiation-induced leukemia cells (also express CD3), while other
tumor cells never express CD4 or CD8. The numbers of total TILs,
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populations of these cells amongmicroscopically counted lymphocytes.
The numbers of CD8+TILs and CD4+TILs were calculated by the % pop-
ulations of those cells, and the number of lymphocytes was countedmi-
croscopically (total TILs).
2.7. Treg Suppression Assay
On day 5 of incubation, iTreg cells were isolated by anti-CD25 mag-
netic separation (Miltenyi Biotec). CD4+ CD25− T cells (Tconv) were
isolated from wild-type spleen cells and labeled with CFSE (Thermo
Fisher Scientiﬁc). Irradiated (40 Gray), T cell-depleted splenocytes
were used as feeder cells. Tconv and iTreg cells were co-cultured, to-
gether with feeder cells containing the anti-CD3mAb, at different ratios
as indicated, and the division of Tconv cells was assessed by dilution of
CFSE on day 3.
2.8. Metabolic Assays
OCRs and ECARs were measured in XFmedium (non-buffered RPMI
1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium
pyruvate) in response to 1 μM oligomycin (Sigma–Aldrich, Kanagawa,
Japan), 10 μM FCCP (Sigma–Aldrich), and 1 μM rotenone (Sigma–Al-
drich)+1 μMantimycin A (Sigma–Aldrich) using the XFe96 Extracellu-
lar Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA). TheFig. 1.Metformin (Met)-induced speciﬁc reduction of Treg cells in tumors but not in the spleen.M
Met dissolved in free drinking water from day 7 after the tumor challenge. The tumor and sple
lymphocytes were stained with ﬂuorescence-labeled antibodies to CD3, CD4, and CD25 or w
detect early apoptotic cells. The ratios of the populations of CD4+CD25+annexin V−/CD4+
CD4+CD25+ T cells was shown for Meth A and RLmale1 tumors. Flow cytometry data are pro
bar graphs as indicated. N = 5 for each group. +, Met administered; −, Met not administe
experiments.proton leakage was calculated according to the following formula:
basal respiration− ATP-linked respiration.
2.9. Western Blot Analysis
Cell lysates were prepared by suspending cells in lysis buffer (PBS,
1% Nonidet P-40, 1 mM phenylmethylsulfonyl ﬂuoride). The lysates
were cleared by centrifugation and subjected to electrophoresis on a so-
diumdodecyl sulfate–polyacrylamide gel. The proteinswere then trans-
ferred to nitrocellulose membranes, blocked with 1–10% dry milk (or
bovine serum albumin) in TBS-T buffer [TBS (10 mM Tris–HCl, pH 7.5,
135 mM NaCl) + 0.05% Tween-20]. Antigen–antibody complexes
were visualized by chemiluminescence with an enhanced chemilumi-
nescence substrate. Anti-S6 (1:1000), anti-pS6 (1:1000), anti-actin
(1:1000) antibodies were purchased from Cell Signaling Technology.
Immunoblot images were cut and rearranged to remove irrelevant in-
formation; however, all lanes were obtained from the same blots with
the same levels of exposure and contrast.
2.10. Sequencing of 16S rRNA Genes
The V3–V4 region of the 16S rRNA gene was ampliﬁed as de-
scribed elsewhere (Klindworth et al., 2013). Mixed samples were
prepared by pooling approximately equal amounts of polymerase
chain reaction (PCR) amplicons from each sample and subjected toice inoculatedwithMethA (A, B), RLmale1 (C, D),MCA (E, F), andMO-5 (G,H)were given
en of each mouse were obtained on days 10 and 13 (or day 14), and the TILs and splenic
ith annexin V and subjected to ﬂow cytometry analysis. Annexin V is a reagent that can
annexin V−are shown as bar graphs as indicated. (I) Annexin V positive population of
duced by pooled TILs from ﬁve mice. % annexin V+CD4+CD25+ population is shown as
red; *P b 0.05; **P b 0.01. The results are representative of at least three independent
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form (Illumina, San Diego, CA, USA) according to the manufacturer's
instruction. 16S rRNA reads were analyzed using Quantitative In-
sights Into Microbial Ecology (QIIME, version 1.8.0). The QIIME pipe-
line takes raw sequence fastq ﬁles and classiﬁes all ﬁlter-passed
reads of 16S V3–V4 sequences obtained from each sample into oper-
ational taxonomic units on the basis of sequence similarity
(Sugahara et al., 2015).
2.11. Statistical Evaluation
Student's t-test was used for statistical evaluations of normally dis-
tributed data.
3. Results
3.1. Tumor Site-Speciﬁc Reduction of CD4+CD25+Regulatory T Cells by
Metformin Administration
To identify tumor-inﬁltrating CD4+CD25+ regulatory T cells (Ti-
Treg) in tumor homogenates, we used the same gating strategy byFig. 2.Decrease of the KLRG1+CD103+ subpopulation, IL-10 production, and CTLA-4 expression
which were given Met (blue circles) or normal feed (red circles) as indicated by the shadow
population in Ti-Treg cells was reduced by Met administration. Treg subpopulations in the
identiﬁed by their expressions of KLRG1 and CD103. The experiment was performed twic
experiment. Bar graphs indicate % ratios of the KLRG1+CD103+ population among CD4+CD2
cell surface CTLA-4 expression were reduced in Ti-Treg cells but not in Treg cells from the sp
and analyzed by ﬂow cytometry. Mean ﬂuorescence of IL-10 and CTLA4 is shown as bar graph
experiments. +, Met administered;−, Met not administered; *P b 0.05; **P b 0.01.which nTreg cells were isolated from the spleen (Suppl. Fig. 1A, B).
About 90% of the isolated CD4+CD25+Treg population was Foxp3-
positive in both spleen and tumor (Suppl. Fig. 1B). A proportional de-
crease in the Treg/CD4+ T cell ratio was apparent in tumors but not
in spleens of the mice taking Met (Suppl. Fig. 2A). Focusing on
annexin V− CD4+CD25+ T cells (i.e., viable populations), we ob-
served aMet-induced decrease in Ti-Treg populations in four distinct
tumors (Fig. 1A to H). This decrease in the number of Tregs in tumors
might be explained by the increase in apoptosis of the cells in tumors
but not in spleens, as indicated by the expression of annexin V
(Fig. 1I, Suppl. Fig. 2B) and cleaved caspase-3 (Suppl. Fig. 3). By con-
trast, Met administration decreased the expression of cleaved
caspase-3 in Foxp3− conventional CD4+T cells (Suppl. Fig. 3A). A de-
tailed analysis of one models, the MCA tumor, demonstrated an in-
crease in the annexin V+ subset of Tregs. Moreover, the absolute
number of CD8+annexin V−cells per tumor volume (mm3) in-
creased signiﬁcantly. Because the number of CD4+CD25+ annexin
V− cells did not change, Met administration resulted in a signiﬁcant
decrease in the ratio of annexin V−Ti-Treg to annexin V− tumor-
inﬁltrating CD8+ T cells (Suppl. Fig. 4). The results suggest that Met
administration increases antitumor immunity.in Ti-Treg cells byMet administration. (A) Tumor growth inmice inoculatedwithMethA,
ed rectangle. N = 10 for each group. (B) Terminally differentiated, a KLRG1+CD103+
spleen, tumor-draining lymph node (TdLN), and TILs of the MethA-bearing mice were
e, and the ﬂow cytometry panels are representative of ﬁve independent mice in one
5+Foxp3+Treg cells in one experiment. N = 5 for each group. (C) IL-10 production and
leen, TdLN by Met administration. The cells were pooled from three mice for each group
s as indicated. N = 3 for each group. The results are representative of three independent
158 Y. Kunisada et al. / EBioMedicine 25 (2017) 154–1643.2. Downregulation of the Effector Molecules of Tumor-Inﬁltrating CD4+-
CD25+ Regulatory T Cells by Metformin Administration
Active effector Treg cells are known to express inhibitory molecules,
such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and IL-10 (Laidlaw
et al., 2016) and are characterized as a KLRG1+CD103+ terminally dif-
ferentiated population (Cheng et al., 2012; Laidlaw et al., 2015).Met ad-
ministration delayed the tumor growth in vivo (Fig. 2A), which was
accompanied by the decreased proportion of KLRG1+ CD103+Treg
cells in tumors, whereas it did not inﬂuence those in tumor-draining
lymph nodes (LNs) and the spleen (Fig. 2B). Intracellular cytokine stain-
ing of Ti-Treg cells, but not that of the spleen and tumor-draining LNs,
revealed a decrease of IL-10 production, and the cell surface level of
CTLA-4 was also decreased (Fig. 2C).
Regarding the energy metabolism, Treg generation is fueled by
fatty acid oxidation, followed by oxidative phosphorylation in mito-
chondria (Michalek et al., 2011; Gerriets et al., 2015). Normal mito-
chondrial function is manifested as appropriate levels of reactive
oxygen species (ROS) production and membrane potential. We
found a decrease in both the membrane potential and ROS produc-
tion in Ti-Treg, caused by Met administration (Fig. 3A, B). Interest-
ingly, the cell surface level of a glucose transporter, GLUT1,
signiﬁcantly increased in Ti-Treg cells (Fig. 3C). The results indicated
that Met reprogrammed the energy metabolism in Ti-Treg cells,
probably shifting to glycolysis rather than oxidativeFig. 3.Met-induced alterations of the mitochondrial membrane potential, ROS production, and
mitochondrial-speciﬁc production of ROS (%MitoSOX+) were reduced in Ti-Treg cells of mice b
ﬁve individual mice in one experiment. The results are representative of two independent expe
andmitochondrial-speciﬁc production of ROS (%MitoSOX+) in Treg cells of the spleen and tumo
as in (A), onday10. (C) Cell surface GLUT1 expressionwas enhanced in Ti-Treg cells byMet adm
Cell surfaceGLUT1 expressionwasmonitored in Treg cells fromTILs ofMethA-bearingmice on d
ﬁvemice bearingMethA. The bar graph data were obtained from ﬁve individual mice. Both resu
administered. *P b 0.05, **P b 0.01, ***P b 0.001.phosphorylation, which might result in a substantially decreased
production of IL-10 and a lower expression of CTLA-4.
3.3. Exposure of Naïve CD4+CD25−Foxp3− T Cells to Metformin Results in
Decreased iTreg Differentiation, Induced by TCR Stimulation in the Presence
of TGF-β
Most tumors are known to produce TGF-β (Derynck and Zhang,
2003), which can be involved in peripheral Treg induction by stimulat-
ing de novo synthesis of the transcriptional factor Foxp3 and can reduce
antitumor immunity (Ghiringhelli et al., 2005; Liu et al., 2007). There-
fore, we considered a possibility of disturbed iTreg generation in tumors
caused by Met administration. We prepared naïve CD4+CD25−T cells,
which were exposed for 6 h to 10 μM Met, a physiologically relevant
plasma concentration in T2D patients who are taking Met (Fig. 4A),
and stimulated with anti-CD3 and anti-CD28 monoclonal antibodies
(mAbs) with TGF-β for 3 days. Cell division was monitored by labeling
the cell surface with carboxyﬂuorescein succinimidyl ester (CFSE), to-
gether with evaluation of the intracellular Foxp3 expression. Met pre-
treatment accelerated the cell division in both cells treated with the
anti-CD3 mAb alone (Fig. 4B, left panel) and anti-CD3 mAb + anti-
CD28mAb (Fig. 4B, right panel). Induction of Foxp3, however, was abso-
lutely dependent on the presence of TGF-β, and surprisingly, it was
downregulated by the Met pretreatment as shown in the histograms
(Fig. 4B). The ratio of Foxp3+/Foxp3− populations did not increase inGLUT1 expression in Ti-Treg cells. (A) Mitochondrial membrane potential (%ΤΜRΕ+) and
earing MethA by Met administration. The data were obtained from the spleen and TILs of
riments. (B) Flow cytometry images on themitochondrial membrane potential (%ΤΜRΕ+)
r. The results are representative of 10 individualmice from two independent experiments,
inistration. Treg cells of the spleen and tumorwere examined for their expression ofGLUT1.
ay 10 after the tumor challenge. The resultswere obtained frompooled spleens and TILs of
lts are representative of two independent experiments. +, Met administered;−, Met not
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panels). Additional 2 days of culture with IL-2 did not result in any up-
ward trend of the ratio (Fig. 4C, right and bottompanels). In the absence
of TGF-β, the ratio of Foxp3+/Foxp3− populations in both Met-treatedFig. 4.Met prevents the differentiation of naïve CD4+CD25− cells into CD4+ CD25+Foxp3+Tr
and incubated for 6 h in the presence or absence of 10 μMMet. (A)Met pretreatment of naïve CD
pretreatedwith orwithoutMet as in (A)were stimulated for 3 dayswith the anti-CD3mAb or a
division and Foxp3 expression were monitored simultaneously. Foxp3 expression was sig
differentiated cells stimulated with anti-CD3 mAb + anti-CD28 mAb in the presence or abs
presence of IL-2 or analyzed on day 3. The relationship between the number of divisions and
Foxp3− was observed with progressive division of cells pretreated with Met. (D) CD25 exp
division. The results in (A) to (D) are representative of four independent experiments.and untreated groups was nearly comparable (Fig. 4C, upper graph).
The results led us to conclude that the Met exposure suppressed the
TGF-β•-induced Foxp3 expression in iTreg cells differentiated from
naïve CD4+CD25−T cells. We also examined the CD25 expression ineg cells. Naive CD4+CD25− cells puriﬁed from BALB/c spleen cells were labeled with CFSE
4+CD25− cells did not affect the expression of CD25 or Foxp3. (B) Naive CD4+CD25− cells
nti-CD3mAb+ anti-CD28mAb in the presence of graded doses of TGF-β, as indicated. Cell
niﬁcantly inhibited in cells pretreated with Met, as shown in the histograms. (C) The
ence of 5 ng/mL TGF-β as in (B) were expanded for an additional 2 days (day 5) in the
the ratio of Foxp3+/Foxp3− was plotted. No additional increase in the ratio of Foxp3+/
ression in Foxp3+ iTreg cells on days 3 and 5 (in C) was examined in parallel with cell
Fig. 5. Reduced inhibitory function and elevated apoptosis of iTreg cells differentiated
from Met-treated naïve CD4+CD25− cells. (A) CD4+CD25+ cells induced as in Fig. 4C
(day 5) were enriched in the iTreg cell population using CD25+ magnet beads. iTreg
cells were incubated with conventional naïve CD4+CD25− T cells (Tconv) labeled with
CFSE at the indicated ratios in the presence of anti-CD3 mAb and rhIL-2 for 3 days for
the Treg suppression assay. iTreg cells that differentiated from naïve CD4 T cells
pretreated with Met exhibited less of an inhibitory effect on Tconv cell division.
(B) iTreg cells (day 3 and day 5 cultures) were induced from CTV-labeled naïve
CD4+CD25− cells of Foxp3Cre-GFP mice. The GFP (Foxp3)-positive population was
characterized as iTreg cells undergoing cell division (gate a) and those without division
(gate b). Only the Met-pretreated iTreg population expanded by IL-2 treatment (day 5,
gate a, bottom panel) was positive for annexin V binding, i.e., undergoing apoptosis.
160 Y. Kunisada et al. / EBioMedicine 25 (2017) 154–164Foxp3+iTreg cells according to cell divisions. The expression level of
CD25 increased in parallel with the progressive cell divisions (Fig. 4D).
On day 3, the level was further enhanced by pretreatment with Met,
while it was downregulated by the additional 2 days of culture com-
pared with the iTreg cells that were not pretreated (Fig. 4D). The impli-
cation of this ﬁnding is not clear at this stage, although the CD25 level
might be associated with the functional activity of Treg cells.
3.4. Functional Reduction and Apoptosis Induction in iTreg Cells Generated
From Naïve CD4 T Cells Exposed to Metformin
We evaluated the activity of the iTreg cells on day 5 by a standard
suppression assay. As expected, the iTreg cells generated from naïve
CD4 T cells pre-exposed to Met showed less suppression against the
cell division of conventional CD4 T cells (Fig. 5A). Because of the signif-
icant increase of the annexin V+ population among the Ti-Treg cells
(Fig. 1I, Suppl. Fig. 2B), we examined the induction of apoptosis in
TGF-β-induced iTreg cells. By staining with cell trace violet (CTV) for
splenic naïve CD4+CD25−T cells puriﬁed from Foxp3–green ﬂuores-
cent protein (GFP) knockin mice (Miyao et al., 2012), we could identify
dividing iTreg cells (Fig. 5B, gate a), distinguished from the non-dividing
Foxp3–GFP-positive population (Fig. 5B, gate b). The cells in gates a and
b were examined for their annexin V binding, and it was revealed that
only iTreg cells dividingwith IL-2 as an apparent annexin V+population
when they were pre-exposed to Met (Fig. 5B, day 5, gate a).
3.5. Metabolic Reprogramming of iTreg Cells Generated From Naïve CD4 T
Cells Exposed to Metformin
The evidence of Met-dependent increase of GLUT1 expression
(Fig. 3) inspired us to investigate the metabolic state of iTreg cells. The
oxygen consumption rate (OCR, pmol/min) was monitored in CD4+T
cells stimulated with TCR signal as indicated (Fig.6A). We found that
Met pretreatment of CD4+T cells followed by stimulation with anti-
CD3 mAb or anti-CD3 mAb and anti-CD28 mAb plus TGF-β increased
thebasal respiration of T cells and their spare respiratory capacity, as de-
termined by the addition of ﬂuoro-carbonyl cyanide phenylhydrazone
(FCCP) (Fig. 6A, upper panel, Fig. 6B, left panel). The upregulation was
not observed in the CD4 T cells stimulated with anti-CD3 mAb and
anti-CD28 mAb in the absence of TGF-β (Fig. 6A, upper panel, Fig. 6B,
left panel), indicating that the metabolic change is linked to TGF-β sig-
naling. Glycolysis, determined by the extracellular acidiﬁcation rate
(ECAR, mpH/min), was also increased in the same manner by the Met
pretreatment (Fig. 6A, lower panel, Fig.6B,middle panel). The decreased
OCR/ECAR ratio due to theMet pretreatment in iTreg indicates the tran-
sition of the metabolic state from oxidative phosphorylation to glycoly-
sis (Fig. 6C). In addition, proton leakage was decreased by the Met
pretreatment (Fig. 6B, right panel), probably linked to the decreased
ROS production in Ti-Treg cells of the mice receiving Met as shown in
Fig. 3A.
3.6. Met-Induced Elevation of mTOR Signaling Impaired iTreg Induction
Next, we tried to ﬁnd why Foxp3 induction was inhibited in naïve
CD4 T cells treated with Met.
Since mTOR signaling is known to act as a negative regulator for
Foxp3 induction in naïve CD4 T cells (Zeng and Chi, 2015), it is possible
that the Met-induced activation of mTOR took place, resulting in the
suppression of the Foxp3 level. To examine this possibility, phosphory-
lation of a downstreammolecule of mTORC1, S6 protein, was examined
by western blotting. The elevation of pS6 was apparent in cells
pretreated with Met, followed by stimulation with TCR in the presence
of TGF-β (Fig. 7A). It was also observed that RA, a speciﬁc inhibitor of
mTORC1, restored the Foxp3 expression (Fig. 7B). In addition, a similar
recovery of Foxp3 by the treatment of cells with CC, an inhibitor of
AMPK was found (Fig. 7B). The results indicate that the Met-inducedFoxp3 inhibition depends on the activities of both mTORC1 and AMPK,
although AMPK activation is known to result in the downregulation of
mTOR activity (Gwinn et al., 2008; Tripathi et al., 2013). Neither Met
treatment nor inhibitors (RA or CC) affected the original level of Foxp3
in nTreg cells obtained from the spleen (Suppl. Fig. 5); therefore, the ef-
fect of Met is restricted to the differentiation of naïve CD4 T cells into
iTreg cells. To investigate whether mTORC1 activation occurs in vivo,
we ﬁnally examined the expressions of pS6 on Ti-Treg. We observed a
signiﬁcant elevation of pS6 in Ti-Treg of mice receiving Met compared
with that in mice not receiving Met (Fig. 7C). Ti-Treg cells with highest
expressions of CD25 was found to contain a larger population of
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was signiﬁcantly greater in mice taking Met than those in the control
mice (Suppl. Fig. 6).
3.7. Met-InducedMetabolic Reprogramming Toward Glycolysis is Linked to
Decreased Foxp3 Expression
Because the target of Met is believed to be mitochondrial complex I,
we examined the effects of rotenone (Rot) (also known to inhibit com-
plex I activity) on Foxp3 expression. Naïve CD4+CD25−T cells were
treated with Met or Rot before, after, or before and after TCR stimula-
tion. We found that only treatment before TCR stimulation reduced
Foxp3 expression (Fig.7D, Suppl. Fig.7A). The effects of Rot were foundFig. 6.Metabolic proﬁles of iTreg cells differentiated from naïve CD4+CD25− cells under differ
(open symbols) Met were stimulated with antibodies against CD3 or CD3 and CD28 for three
using a Seahorse XF96 analyzer with the addition of anti-mitochondrial reagents, oligomycin,
three independent experiments are shown. (B) Basal levels of OCR, ECAR, and proton leakage
modiﬁed Eagle's medium without glutamate. (C) The ratio of ECAR/OCR was plotted as a bar gto be exactly the same as those of Met (Fig.7D). Since the context-
dependent nature of the effect of Met and Rot was puzzling, we exam-
ined the metabolic proﬁles resulting from each treatment condition.
We found that an increased ECAR was unique to Met pretreatment
and that the OCR/ECAR ratio was signiﬁcantly lower only with Met pre-
treatment (Suppl. Fig.7B). These results again suggest that metabolic
reprogramming toward glycolysis rather than oxidative phosphoryla-
tion is associated with Foxp3 downregulation.
4. Discussion
This report demonstrated a possible contribution of Met in shaping
the tumor microenvironment into a favorable state of antitumorent conditions. (A) Naïve CD4+CD25− cells pretreated with (closed symbols) or without
days in the presence or absence of TGF-β, as indicated. The OCR and ECAR were assayed
FCCP, rotenone (R), antimycin (A), and 2-deoxyglucose (2-DG). Representative data from
are shown under each culture condition as in (A). The ECAR was assayed in Dulbecco's
raph. Notably, Met pretreatment decreased OCR/ECAR in iTreg. *P b 0.05; **P b 0.01.
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cells with the KLRG1+CD103+ phenotype. To the best of our knowl-
edge, Met is the only prescribed medicine that can speciﬁcally reduce
Treg cells at tumor sites, without affecting other peripheral tissues. Re-
garding mechanistic insight, we demonstrated that Met-pretreatment
of naïve CD4T cells inhibits TGF-β-dependent iTreg generation through
the activation of mTORC1 followed by the downregulation of Foxp3 ex-
pression. In addition to our previous observation suggesting thatMet in-
duces reactivation of exhausted CD8 TILs, the present study further
reinforces the idea that the immune system mediates the Met-
induced anticancer effect. Met treatment is accompanied by a signiﬁ-
cant reduction of the Treg/CD8 T-cell ratio in a tumor microenviron-
ment, which is associated with a favorable prognosis for cancer
patients (Sato et al., 2005).
Only the treatment of naïve CD4T cells with Met or Rot before TCR
stimulation resulted in a downregulation of Foxp3 in proliferatingFig. 7. Involvement of mTORC1 activation in iTreg cells differentiated from Met-treated naïv
pretreated naïve CD4+CD25− T cells in response to different stimulations of TCR for 30 min,
of two independent experiments. (B) Foxp3 expression decreased in iTreg cells differentiate
during Met pretreatment restored Foxp3 expression. The histogram results are representative
N = 3. (C) The level of pS6 protein increased in Ti-Treg cells of mice receiving Met. The histo
bar graph data were obtained from ﬁve individual mice. Both results are representative of th
before TCR stimulation resulted in a decrease in Foxp3 expression. Pre-treatment assay:
stimulation. Post-treatment assay: CD4+CD25− T cells were treated with culture medium for
stimulation, Foxp3 expression was examined. The histogram results are representative of thre
**P b 0.01; ***P b 0.001.CD4T cells. Of note, the presence of Met throughout the experiments
did not result in the downregulation of Foxp3. In the Seahorse analysis,
we observed that increased glycolysis is a hallmark of Met
pretreatment-induced iTreg cells but not of iTreg cells treatedwithmet-
formin throughout the experiments. The results suggest that the effects
observed in vitro are caused by a rebound effect and not by any speciﬁc
effect of pretreatment with Met.
Nonetheless, the context-dependent effects of Met and Rot allowed
us to consider what occurs in vivo by treating tumor-bearing mice
with Met. The intake of Met dissolved in free-access drinking water
(5 mg/mL) by mice is known to result in plasma concentrations of ap-
proximately 1.7 μg/mL, similar to those of patients with T2D who took
Met (0.5–2 μg/mL; Memmott et al., 2010). However, whether the
same concentration is reached in the tumor microenvironment is un-
clear. Recently, Scharping et al. raised the possibility that Met is prefer-
entially incorporated by tumors as opposed to T lymphocytes, as thee CD4+CD25−cells. (A) The level of phosphorylated S6 protein (pS6) increased in Met-
as indicated. Each lane includes lysates from 2 × 105 cells. The results are representative
d from Met-treated naïve CD4+CD25−cells. The presence of rapamycin or compound C
of three independent experiments, and the individual results are plotted as a bar graph.
gram data were obtained from pooled spleens and TILs of ﬁve mice bearing MethA. The
ree independent experiments. (D) Only Met (or Rot)-pretreatment of naïve CD4T cells
CD4+CD25− T cells were treated with Met (or Rot) for 6 h and washed before TCR
6 h and then incubated with Met (or Rot) during TCR stimulation. Three days after TCR
e independent experiments, and the individual data are plotted as a bar graph. *P b 0.05;
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than in tumor cells (Scharping et al., 2016). This observation indicates
that although peripheral blood naïve CD4T cells exposed toMetmigrate
into tumors, the Met concentration in tumors might be extremely low.
Accordingly, naïve CD4T cells exposed to Met in the periphery migrate
into tumors and then fail to differentiate into Foxp3-positive regulatory
T cells, even with TCR stimulation in the presence of TGF-β. This phe-
nomenon is supported by the ﬁnding that in vitro iTregs were not gen-
erated fromnaïve CD4T cells thatwere pretreatedwithMet. In addition,
the authors suggested that oxygenation of the tumor microenviron-
ment by Met may facilitate antitumor immunity elicited by the anti-
PD-1 antibody. Oxygen becomes available to the surrounding immune
cells since tumor cell respiration is suppressed by Met. Hence, Met-
induced increase in oxygen concentrationmight impact the differentia-
tion/survival and function of T cells, including Treg cells.
Because increased glycolysis is associated with mTORC1 activation,
alternative pathways that activate mTORC1 might interfere with the
downregulation of Foxp3. In fact, metformin-induced downregulation
of Foxp3 is reversed by rapamycin, indicating that mTORC1 activation
is essential for the decrease in iTreg generation. Although metformin
is known to activate AMPK, resulting in the downregulation of
mTORC1 activity; however, this downregulation is not observed
in vivo. Thus, metformin administration results in the activation of
mTORC1, as indicated by enhanced phosphorylation of the downstream
S6 protein. Therefore, an alternative pathway that remains to be identi-
ﬁed must link the action of metformin to mTORC1 activation in vivo.
Such a pathwaymust be associatedwith the TCR signaling that ismainly
activated in tumors but not in peripheral lymphoid tissues. This scenario
might occur in vivo, which would explain whymetformin induces a de-
crease in Treg in tumors but not in peripheral lymphoid organs. Howev-
er, this possibility warrants further investigation in future studies.
Seemingly, Met-induced decreased production of IL-10 and a lower
expression of CTLA-4 of Ti-Treg cells are associated with metabolic
reprogramming toward glycolysis. Evidence of enhanced Glut-1 expres-
sion on the cell surface and of decreasedmitochondrialmembranepoten-
tial byMet treatmentmight support the change ofmetabolic proﬁle from
oxidative phosphorylation to glycolysis. In addition, a recent report sug-
gested that Foxp3 inhibits glycolysis through the suppression of Myc
gene expression (Angelin et al., 2017), which might support the concept.
Further studies are required to elucidate the link between increased gly-
colysis and decreased IL-10 and CTLA-4 in Ti-Treg cells.
A recent report has indicated that Met treatment of T2D patients af-
fects the gut microbiome (Forslund et al., 2015), and these commensal
bacteria regulate the anticancer immune effect induced by a CpG oligo-
nucleotide (Iida et al., 2013) and/or cyclophosphamide (Viaud et al.,
2013). In our mouse model, Met is administered by dissolving it in
free drinkingwater. It is possible that oral intake ofMet affects the com-
position of gutmicrobiota, which regulates the Treg development in the
gut (Atarashi et al., 2011; Furusawa et al., 2013), to modulate the im-
mune response against tumors. Therefore, we performed 16S ribosomal
RNA (rRNA) sequencing of the fecal microbiota of Met-treated and un-
treatedMO5-bearingmice. Consequently, we found no signiﬁcant alter-
ations in the fecal microbiota of the mice treated with Met (Suppl.
Fig. 8), indicating that the change of intestinal microbiota is negligible.
In summary, we provide compelling evidence that Met, at physiolog-
ical concentrations, inhibits TGF-β-dependent iTreg generation in vitro
and attenuates CD4+CD25+Treg in tumors, both of which seem to be as-
sociated with mTORC1 activation and metabolic reprogramming toward
glycolysis. Although themechanismunderlyingmTORC1 activation is un-
clear, these results might help in the development of strategies to control
Treg proliferation in a tumor microenvironment.
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